Phase 3
Completed N=39,876
Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer
Cardiovascular Disease · Cerebrovascular Disorders · Coronary Disease · Heart Failure
Source: ClinicalTrials.gov NCT00000479 ↗
Enrolled (actual)
39,876
Serious AEs
0.2%
Results posted
Jun 2012
Primary outcomePrimary: Number of Participants With Major Cardiovascular Events (a Combined Endpoint of Nonfatal Myocardial Infarction, Nonfatal Stroke, and Total Cardiovascular Death) — 245; 250; 232; 272 Participants
Summary
The purpose of this study is to evaluate the effects of low-dose aspirin and vitamin E in primary prevention of cardiovascular disease and cancer in apparently healthy women.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Major Cardiovascular Events (a Combined Endpoint of Nonfatal Myocardial Infarction, Nonfatal Stroke, and Total Cardiovascular Death) |
245; 250; 232; 272; 113; 133 | — |
| PRIMARY Number of Participants With Cancer, Excluding Nonmelanoma Skin Cancer |
722; 721; 716; 706; 132; 156 | — |
Eligibility Criteria
Inclusion Criteria
- Healthy women
- No previous history of cardiovascular disease or cancer
- No contraindications to aspirin or vitamin E
Data sourced from ClinicalTrials.gov (NCT00000479). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.